Roche's Alecensa latest beneficiary of faster China drug approvals

Roche’s Alecensa lung cancer medicine became the latest beneficiary of China’s efforts to speed up approvals in the world’s second-biggest drug market, which is gaining importance for global pharmaceuticals companies’ growth plans.